Abstract
Finding an effective therapy able to slow Neurocognitive Disorder’s (NCD) progression represents an ambitious purpose of biomedical research. In June 2021, the Food and Drug Administration approved Aducanumab for the treatment of Alzheimer’s disease – the most common cause of dementia worldwide [1]. This drug is a monoclonal antibody that would be cause amyloid-β plaques reduction in the brain [2]. Whether its effectiveness will be confirmed or not, the fact remains that the patients that will benefit the most from any treatment are the ones suffering from mild NCD. Mild NCD is a clinically insidious and difficult-to-diagnose disorder, and consequently, the development and the spread of screening methods are necessary to early intercept these subjects.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
